Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions highlight the importance of achieving higher doses of heart failure medications within a short period, using terms like 'all efforts should be made' and 'rapid uptitration,' reflecting strong support and perceived significance. The tone and context show excitement for the potential impact on patient outcomes and clinical management, emphasizing both the scientific importance and practical implications of the findings.
Most discussions support the importance of rapidly uptitrating heart failure medications, indicating agreement with the study's findings.
Posts show high interest, with many emphasizing the significance of the research and referencing specific trial names and clinical practices.
Comments refer to the methods, results, and implications, demonstrating moderate to deep engagement with the topic.
The widespread focus on optimizing treatment suggests this publication could influence clinical guidelines and practice changes.
When patients with acute heart failure can tolerate higher doses of guideline-directed medical therapy, results suggest that all efforts should be made to rapidly uptitrate to optimal doses of the 3 and (likely) 4 pillars of HF medications. https://t.co/OR8WefrTCM
When patients with acute heart failure can tolerate higher doses of guideline-directed medical therapy, results suggest that all efforts should be made to rapidly uptitrate to optimal doses of the 3 and (likely) 4 pillars of HF medications. https://t.co/29KsHWR027
Among patients with AHF randomly assigned to high-intensity care, achieving higher doses of HF GDMT within 2 wks after
【追加解析: STRONG-HF】急性心不全患者において、GDMT（RAS阻害薬、β遮断薬およびMRA）の最適な投与量に対する投与量の割合の平均値の10%の増加は、180日心不全再入院または全原因死亡の減少と関連した。90日時点のQoLはGDMTの投与量が多い患者でより改善が見られた。 #ペ読 https://t.co/NfO23lWl6x
Join our scientific team as we discuss the most clinically impactful papers of the month, including findings on cardiac-resynchronization therapy and its long-term benefits over traditional defibrillators for heart…
The STRONG-HF trial explored the rapid uptitration of guideline-directed heart failure therapy (GDMT) after hospitalization. The study found over 90% of patients achieved optimal GDMT doses in two weeks, leading to…
2 min cardiology（臨床論文、担当：井上巧） Optimization of Evidence-Based Heart failure Medications After an Acute Heart Failure Admission Gad Cotter et al. JAMA Cardiol. 2024; 9(2): 114-124 https://t.co/9ZeEYzftFN →
Strong-HFはフルテキストなんとかもらって読んでたけど、アクセスは制限、、、Strong-HFの二次分析の論文はフリーアクセスやったし、こっちはこっちで分かりやすかった！ Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission https://t.co/HxJ8VqQIFy
Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission - A Secondary Analysis of the STRONG-HF Randomized Clinical Trial
RT @medicalport_app: Have you already listened to the podcast Best of the Month – January 2024? This episode turns the top papers publishe…
RT @medicalport_app: Have you already listened to the podcast Best of the Month – January 2024? This episode turns the top papers publishe…
Have you already listened to the podcast Best of the Month – January 2024? This episode turns the top papers published in January into captivating conversations with our scientific team!
Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission https://t.co/YX5PoSknpz
Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized Clinical Trial | Cardiology | JAMA Cardiology | JAMA Network
RT @ZHeart11768530:
RT @ZHeart11768530:
RT @ZHeart11768530:
Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission https://t.co/ON3dpEdySn
RT @JAMACardio: When patients with acute heart failure can tolerate higher doses of guideline-directed medical therapy, results suggest tha…
RT @JAMACardio: When patients with acute heart failure can tolerate higher doses of guideline-directed medical therapy, results suggest tha…
RT @JAMACardio: When patients with acute heart failure can tolerate higher doses of guideline-directed medical therapy, results suggest tha…
RT @ZHeart11768530:
RT @JAMACardio: When patients with acute heart failure can tolerate higher doses of guideline-directed medical therapy, results suggest tha…
RT @JAMACardio: When patients with acute heart failure can tolerate higher doses of guideline-directed medical therapy, results suggest tha…
RT @JAMACardio: When patients with acute heart failure can tolerate higher doses of guideline-directed medical therapy, results suggest tha…
RT @JAMACardio: When patients with acute heart failure can tolerate higher doses of guideline-directed medical therapy, results suggest tha…
When patients with acute heart failure can tolerate higher doses of guideline-directed medical therapy, results suggest that all efforts should be made to rapidly uptitrate to optimal doses of the 3 and (likely) 4 pillars of HF medications. https://t.co/29KsHWR027
RT @medicalport_app:
Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission - A Secondary Analysis of the STRONG-HF Randomized Clinical Trial
Siempre buscar dosis máximas toleradas Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission https://t.co/Z5GuZ4x93h
Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized Clinical Trial | Cardiology | JAMA Cardiology | JAMA Network https://t.co/IbsCHqcZVC
Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission https://t.co/AxVG5LFDVk
Full article open access #FOAMed : https://t.co/SZGfFEPUa5
【追加解析: STRONG-HF】急性心不全患者において、GDMT（RAS阻害薬、β遮断薬およびMRA）の最適な投与量に対する投与量の割合の平均値の10%の増加は、180日心不全再入院または全原因死亡の減少と関連した。90日時点のQoLはGDMTの投与量が多い患者でより改善が見られた。 #ペ読 https://t.co/NfO23lWl6x
Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized Clinical Trial | Cardiology | JAMA Cardiology | JAMA Network✅☑️✅☑️ https://t.co/Ry5SDsnBDA
Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission https://t.co/4LzFKHd20u
RT @JAMACardio: When patients with acute heart failure can tolerate higher doses of guideline-directed medical therapy, results suggest tha…
RT @JAMACardio: When patients with acute heart failure can tolerate higher doses of guideline-directed medical therapy, results suggest tha…
RT @dar_louis:
RT @gcfmd: Among patients with AHF randomly assigned to high-intensity care, achieving higher doses of HF GDMT within 2 wks after
RT @JAMACardio: When patients with acute heart failure can tolerate higher doses of guideline-directed medical therapy, results suggest tha…
When patients with acute heart failure can tolerate higher doses of guideline-directed medical therapy, results suggest that all efforts should be made to rapidly uptitrate to optimal doses of the 3 and (likely) 4 pillars of HF medications. https://t.co/OR8WefrTCM
RT @dar_louis:
RT @dar_louis:
RT @gcfmd: Among patients with AHF randomly assigned to high-intensity care, achieving higher doses of HF GDMT within 2 wks after
RT @dar_louis:
RT @FormigaFrancesc: Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission https://t.co/Rat9rSc0y…
RT @dar_louis:
RT @dar_louis:
Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission https://t.co/Rat9rSc0yS @IcyfaSemi @Medtorek @SABOURETCardio
RT @gcfmd: Among patients with AHF randomly assigned to high-intensity care, achieving higher doses of HF GDMT within 2 wks after
RT @gcfmd: Among patients with AHF randomly assigned to high-intensity care, achieving higher doses of HF GDMT within 2 wks after
RT @ZHeart11768530: Optimization of Evidence-Based #HF drugs After an #AHF Admission: A 2ry Analysis of STRONG-HF Trial ✅ When pts tolera…
Optimization of Evidence-Based #HF drugs After an #AHF Admission: A 2ry Analysis of STRONG-HF Trial ✅ When pts tolerate higher doses of GDMT, all efforts should be made to rapidly uptitrate to optimal doses of the 3 & (likely) 4 pillars of HF drugs https://t.co/hxYuCscWhk https://t.co/wa3TBaOGKq
RT @gcfmd: Among patients with AHF randomly assigned to high-intensity care, achieving higher doses of HF GDMT within 2 wks after
Among patients with AHF randomly assigned to high-intensity care, achieving higher doses of HF GDMT within 2 wks after